TNFRSF17 and plasma cell myeloma: Therapies targeting BCMA are undergoing extensive development in the myeloma field, and as of late 2020 belantamab mafodotin, an antibody drug conjugate, has been FDA approved for the treatment of relapsed multiple myeloma.